CytoDyn color logo - no R.png
CytoDyn Announces FDA Has Lifted Clinical Hold
February 29, 2024 08:30 ET | CytoDyn Inc.
Webcast to Provide Company Update on March 5, 2024 VANCOUVER, Washington, Feb. 29, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company...
CytoDyn color logo - no R.png
CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma
February 01, 2024 08:30 ET | CytoDyn Inc.
VANCOUVER, Washington, Feb. 01, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
CytoDyn color logo - no R.png
CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO
January 29, 2024 08:30 ET | CytoDyn Inc.
VANCOUVER, Washington, Jan. 29, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
CytoDyn color logo - no R.png
CytoDyn Announces Webcast to Provide Company Update
December 07, 2023 16:00 ET | CytoDyn Inc.
VANCOUVER, Washington, Dec. 07, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
CytoDyn color logo - no R.png
CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO
November 21, 2023 08:30 ET | CytoDyn Inc.
VANCOUVER, Washington, Nov. 21, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
CytoDyn color logo - no R.png
November 2023 Letter to Shareholders
November 03, 2023 16:02 ET | CytoDyn Inc.
VANCOUVER, Washington, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Dear Shareholders, We write to provide an update on CytoDyn Inc. (“CytoDyn” or “Company”), and to thank you for your continued support of...
CytoDyn color logo - no R.png
CytoDyn Announces Company Updates and Investment Community Update Webcast
July 11, 2023 16:05 ET | CytoDyn Inc.
Claim Filed in Former CRO Litigation for Damages Exceeding $100M Dr. Arman Returns from Medical Leave as SVP of Business Operations Webcast to be held Monday, July 24th, 2023, at 1 PM PT / 4 PM ET ...
CytoDyn color logo - no R.png
CytoDyn Announces President Takes Medical Leave of Absence
May 24, 2023 17:05 ET | CytoDyn Inc.
Antonio Migliarese assumes interim President roleDr. Melissa Palmer appointed interim Chief Medical OfficerDr. Salah Kivlighn joins CytoDyn as clinical and strategic advisor VANCOUVER, Washington,...
CytoDyn color logo - no R.png
CytoDyn to Hold Webcast to Provide a Company Update
April 05, 2023 08:30 ET | CytoDyn Inc.
VANCOUVER, Washington, April 05, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
CytoDyn color logo - no R.png
CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO
December 23, 2022 08:00 ET | CytoDyn Inc.
VANCOUVER, Washington, Dec. 23, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...